Research Article| Volume 49, ISSUE 2, P140-147, October 15, 2004

A short study in the treatment of hot flashes with buccal administration of 17-β estradiol


      Objective: To assess the efficacy and safety of 17-β estradiol buccal tablets in reducing hot flush frequency (HFF) in postmenopausal women.
      Methods: Estradiol buccal tablets containing 0.05, 0.1, 0.2, or 0.4 mg or placebo were administered for 28 days to 99 postmenopausal women in a randomized, double-blind study; 19 premenopausal women were studied concurrently for comparison of laboratory data. Objective and subjective assessments of HFF were obtained along with measures of estradiol, estrone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH).
      Results: Measurements of HFF revealed significant decreases from baseline in all estradiol groups (P<0.01). In the 0.4 mg group, HFF decreased significantly compared to placebo (P<0.01). All estradiol doses produced similar improvement in the vaginal maturation index. Mean serum estradiol levels increased as doses increased but were lower than in the premenopausal subjects. Mean serum FSH and LH levels decreased in all estradiol groups but not to the levels of the premenopausal subjects; the greatest decrease occurred at the two highest estradiol doses.
      Conclusion: A numerical dose–response relationship with hot flushes was seen in this pilot study comparing 0.05, 0.1, 0.2, and 0.4 mg buccal estradiol. Only 0.4 mg 17-β estradiol significantly reduced the occurrence of hot flushes compared to placebo.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McKinlay S.M.
        • Jefferys M.
        The menopausal syndrome.
        Br. J. Prev. Soc. Med. 1974; 28: 108-115
        • Ettinger B.
        • Pressman A.
        • Silver P.
        Effect of age on reasons for initiation and discontinution of hormone replacement therapy.
        Menopause. 1999; 6: 282-289
        • Judd H.L.
        • Meldrum D.R.
        • Deftos L.J.
        • Henderson B.E.
        Estrogen replacement therapy: indications and complications.
        Ann. Int. Med. 1983; 98: 195-205
        • Recker R.R.
        • Saville P.D.
        • Heaney R.P.
        Effect of estrogens and calcium carbonate on bone loss in postmenopausal women.
        Ann. Int. Med. 1977; 87: 649-655
        • Geola F.L.
        • Frumar A.M.
        • Tataryn I.V.
        • Lu K.H.
        • Hershman J.M.
        • Eggena P.
        • et al.
        Biological effects of various doses of conjugated equine estrogens in postmenopausal women.
        J. Clin. Endocrinol. Metab. 1980; 51: 620-625
        • Pfeffer R.I.
        Estrogen use, hypertension and stroke in postmenopausal women.
        J. Chronic. Dis. 1978; 31: 389-398
        • Hulley S.
        • Grady D.
        • Bush T.
        • Furberg C.
        • Herrington D.
        • Riggs B.
        • Vittinghoff E.
        • for the Heart and Estrogen/Progestin Replacement Study Research Group
        Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
        JAMA. 1998; 280: 605-613
        • Steingold K.A.
        • Laufer L.
        • Chetkowski R.J.
        • Defazio J.D.
        • Matt D.W.
        • Meldrum D.R.
        • Judd H.L.
        Treatment of hot flashes with transdermal estradiol administration.
        J. Clin. Endocrinol. Metab. 1985; 61: 627-632
        • Gordon S.F.
        Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
        Am. J. Obstet. Gynecol. 1995; 173: 998-1004
        • Good W.R.
        • John V.A.
        • Ramirez J.M.
        • Higgins J.E.
        Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms.
        Climacteric. 1999; 2: 29-36
        • Speroff L.
        • Whitcomb R.W.
        • Kempfert N.J.
        • Boyd R.A.
        • Paulissen J.B.
        • Rowan J.P.
        Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
        Obstet. Gynecol. 1996; 88: 587-592
        • de Vrijer B.
        • Snijders M.P.M.L.
        • Troostwijk A.L.
        • Thé S.
        • Iding R.J.
        • Friese S.
        • et al.
        Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
        Maturitas. 2000; 34: 47-55
        • Utian W.H.
        • Shoupe D.
        • Bachmann G.
        • Pinkerton J.V.
        • Pickar J.H.
        Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
        Fertil. Steril. 2001; 75: 1065-1079
        • Tataryn I.V.
        • Lomax P.
        • Meldrum D.R.
        • Bajorek J.G.
        • Chesarek W.
        • Judd H.L.
        Objective techniques for the assessment of postmenopausal hot flashes.
        Obstet. Gynecol. 1981; 57: 340-344
        • Meldrum D.R.
        • Shamonki I.M.
        • Frumar A.M.
        • Tataryn I.V.
        • Chang R.J.
        • Judd H.L.
        Elevations in skin temperature of the finger as an objective index of postmenopausal hot flashes: standardization of the technique.
        Am. J. Obstet. Gynecol. 1979; 135: 713-717
        • Laufer L.R.
        • DeFazio J.L.
        • Lu J.K.H.
        • Meldrum D.R.
        • Eggena P.
        • Sambhi M.P.
        • et al.
        Estrogen replacement therapy by transdermal estradiol administration.
        Am. J. Obstet. Gynecol. 1983; 146: 533-540
        • Yoshimura T.
        • Okamura H.
        Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women.
        Maturitas. 2001; 39: 253-257
        • Chetkowski R.J.
        • Meldrum D.R.
        • Steingold K.A.
        • Randle D.
        • Lu J.K.
        • Eggena P.
        • et al.
        Biologic effects of transdermal estradiol.
        N. Engl. J. Med. 1986; 314: 1615-1620
        • Rigg L.A.
        • Milanes B.
        • Villanueva B.
        • Yen S.S.
        Efficacy of intravaginal and intranasal administration of micronized estradiol-17beta.
        J. Clin. Endocrinol. Metab. 1977; 45: 1261-1264
        • Buch A.
        • Shen L.
        • Kelly S.
        • Sahota R.
        • Brezovic C.
        • Bixler C.
        • Powell J.
        Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
        Menopause. 1998; 5: 107-112